Corporate Update
Avant Diagnostics, Inc. Corporate Update Washington, DC., May 8, 2019 – Avant Diagnostics, Inc. hereby provides the following corporate update to the Company’s shareholders. A copy of the update can also be found on the Company’s website at www.avantdiagnostics.com Dear Avant Shareholders: Thank you for your continued support of Avant Diagnostics, Inc. (“Avant” or the […]
Adds Two Esteemed, Internationally Recognized Board Members and Files Its 2016 10-K in Preparation of Getting Current With The SEC
AVANT DIAGNOSTICS ADDS TWO ESTEEMED, INTERNATIONALLY RECOGNIZED BOARD MEMBERS AND FILES ITS 2016 10-K IN PREPARATION OF GETTING CURRENT WITH THE SEC Avant Diagnostics, Inc. (“Avant” or the “Company”) (OTC Pink: AVDX), today announced the addition of two internationally known oncology experts, Dr. Rajesh Shrotriya, M.D. and Andy DeLaO, to its Board of Directors, the […]
Present at LD Micro
Washington, DC USA – June 1, 2018 – Avant Diagnostics, Inc. (OTC Pink: AVDX) (the “Company,” or AVDX), a healthcare data generating technology company that specializes in biomarker tests that are being planned or developed in multiple areas of oncology, today announced that its new President & CEO, Mick Ruxin, M.D., will be presenting a […]
Announces Restructuring and Private Placement
Washington, DC – May 30, 2018 – Avant Diagnostics, Inc. (“Avant”) (OTC: AVDX), an oncology-focused healthcare data-generating solutions company commercializing the proprietary Theralink® phospho-protein biomarker platform across multiple cancers, today announced that it has entered into securities purchase agreements with accredited investors pursuant to which the Company sold 650,000 shares of the Company’s newly designated […]